These properties allow the use of antibodies directed against CD33 as a treatment for AML, in addition to the fact that CD33 is expressed in approximately 90% of AML cases, as observed with the presence of the antigen in more than 20% of blasts of Leukemic patients [9]. The gene discussed is CD33; the disease is acute myeloid leukemia.